Exosome-related immune signatures and peripheral blood assays predict prognosis and immunotherapy response in hepatocellular carcinoma
In this study, we identify a novel signature based on TDEI genes that has the potential to be a biomarker for predicting the prognosis and immunotherapy response for HCC. Peripheral blood tests can be used to predict the response to HCC immunotherapy. In our study, we provide an immunologic perspective for the development of precision therapy for HCC.
Authors
- Lili Mi
- Xiaoling Duan (ORCID: https://orcid.org/0000-0003-2219-3467)
- M. Zhao
- Ruolian Gao
- Meng Zhang
- Fei Yin
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.3389/fcell.2025.1696790
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hebei Medical University